Biosynex SA (0DL.F)
- Previous Close
4.2350 - Open
4.0700 - Bid 4.0450 x --
- Ask 4.1350 x --
- Day's Range
4.0700 - 4.0700 - 52 Week Range
4.0700 - 10.8400 - Volume
1,073 - Avg. Volume
19 - Market Cap (intraday)
44.012M - Beta (5Y Monthly) -2.37
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 16, 2022
- 1y Target Est
--
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers medical devices for in vitro diagnosis in the form of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers, oxymeters, and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
www.biosynex.comRelated News
Performance Overview: 0DL.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0DL.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0DL.F
Valuation Measures
Market Cap
44.01M
Enterprise Value
68.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.43
Price/Book (mrq)
0.32
Enterprise Value/Revenue
0.71
Enterprise Value/EBITDA
-58.40
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.39%
Return on Assets (ttm)
-6.20%
Return on Equity (ttm)
-21.54%
Revenue (ttm)
97M
Net Income Avi to Common (ttm)
-34.33M
Diluted EPS (ttm)
-3.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
45.32M
Total Debt/Equity (mrq)
49.19%
Levered Free Cash Flow (ttm)
-42.34M
Company Insights: 0DL.F
0DL.F does not have Company Insights